Oncology Central

Adoptive cell immunotherapy: ASCO names clinical cancer Advance of the Year

0
The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.

Released today ahead of World Cancer Day, their report – Clinical Cancer Advances 2018: ASCO’s 13th Annual Report on Progress Against Cancer – emphasizes the impressive advancements that have been made in both adoptive cell immunotherapy and precision medicine.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.